Last reviewed · How we verify
AB-SA01
AB-SA01 is a novel antimicrobial agent that targets and disrupts bacterial cell membranes.
AB-SA01 is a novel antimicrobial agent that targets and disrupts bacterial cell membranes. Used for Treatment of complicated urinary tract infections caused by Gram-negative bacteria.
At a glance
| Generic name | AB-SA01 |
|---|---|
| Sponsor | Armata Pharmaceuticals, Inc. |
| Drug class | Antimicrobial |
| Target | lipopolysaccharides |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
AB-SA01 works by binding to specific lipopolysaccharides on the surface of Gram-negative bacteria, ultimately leading to cell lysis and death. This mechanism of action is distinct from traditional antibiotics, which often target specific enzymes or proteins within bacterial cells.
Approved indications
- Treatment of complicated urinary tract infections caused by Gram-negative bacteria
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic
- Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AB-SA01 CI brief — competitive landscape report
- AB-SA01 updates RSS · CI watch RSS
- Armata Pharmaceuticals, Inc. portfolio CI